YieldMax MRNA Option Income Strategy ETF (MRNY)

The YieldMax MRNA Option Income Strategy ETF (MRNY) is a nontraditional equity fund launched in October 2023 that treats Moderna’s stock not as an asset to own outright, but as a volatility mine from which to extract steady income. Instead of buying and holding shares, MRNY systematically sells call spreads — a two-legged options strategy that sells a higher-strike call and buys a lower-strike call, pocketing the difference in premiums while capping any gains the stock might realize above the sold call’s strike.

The underlying logic is simple: Moderna, like most large biotechnology companies, trades with substantial volatility. That volatility translates into expensive option premiums. Rather than let that premium evaporate unused, MRNY harvests it week after week, converting it into distributions paid to shareholders. The trade-off is explicit and structural. Shareholders surrender all gains above the sold call strike in exchange for those weekly payouts. If Moderna rises sharply, shareholders in MRNY forgo those gains. If Moderna falls, the puts offset some loss, but capital erosion remains.

The fund is actively managed and does not hold Moderna shares directly. Instead, it holds cash and US Treasury securities as collateral against the options positions it writes. The synthetic structure keeps the strategy efficient — the fund does not tie capital up in equity that must be held; instead, it positions itself to sell premium and distribute the proceeds. This collateralization also means the fund can operate without owning the underlying stock, a structural difference from covered-call strategies that require share ownership.

MRNY’s distribution rate has historically run well above bond yields and mainstream equity dividends, typically in the range of 70% annualized when measured on the fund’s net asset value. That figure, however, conceals an important reality: much of the reported distribution consists of return of capital rather than investment income. Shareholders are receiving their own money back as distributions, which reduces the fund’s per-share net asset value over time. This is not fraud; it is disclosed in the fund’s reports. But it means a shareholder cannot simply annualize the distribution rate and expect to pocket that percentage as real income. The fund is, in essence, paying out a portion of itself to shareholders each week.

Liquidity matters here. The fund is small by ETF standards, with roughly 83 million dollars in net assets as of mid-2026. Its bid-ask spread is tight — trading costs are negligible for most investors. But the single-stock focus creates concentration risk that diversified portfolios avoid. Moderna’s business is real and important, but its fortunes turn on clinical trials, regulatory decisions, and product commercialization. A sharp decline in MRNA would harm MRNY shareholders directly, and the sold calls offer limited downside protection.

The fund’s expense ratio is 0.99% annually — steep relative to a broad stock ETF but reasonable for active options management. The real cost lies in the structural trade-off: the upside cap. If Moderna’s shares double, MRNY shareholders will have missed most of that move, having exchanged it for a steady income stream that kept pace with volatility but not with directional gains.

Suitable for investors who prioritize current income over capital appreciation, are comfortable with single-stock concentration, and understand that option income strategies can lose money sharply when the underlying stock declines significantly. Not suitable for buy-and-hold investors seeking wealth accumulation or anyone who cannot afford to lose principal.